Increased risk of hip fracture is seen primarily in patients treated with insulin, while T2DM patients treated with any glucose control medication are consistently at increased risk of non-skeletal fall injuries (Wallander et al., 2017). This evidence concerns the gene INS and type 2 diabetes mellitus.